Posted On 31-07-2025

• Increasing Prevalence of Sepsis and Hospital-Acquired Infections: The growing incidence of sepsis cases and hospital-acquired infections is a key driver for the North America market. Centers for Disease Control and Prevention (CDC) reports that over 1.7 million adults in the U.S. develop sepsis annually, leading to high demand for advanced diagnostic tools. Companies such as bioMérieux have responded with the launch of advanced blood culture identification systems like BacT/ALERT® VIRTUO®, providing quicker and more accurate diagnosis to save lives.
• Technological Advancements and Integration of AI: The integration of artificial intelligence and machine learning into sepsis diagnostics is significantly reducing diagnostic times and improving accuracy. For example, Thermo Fisher Scientific recently enhanced its sepsis diagnostic platform to detect bacterial infections more rapidly, reducing time to result from days to hours. This technological leap drives adoption among hospitals seeking to improve patient outcomes and lower mortality rates.

• Emergence of Point-of-Care (POC) Testing: The shift towards point-of-care testing for early detection of sepsis is transforming the diagnostic landscape. Leading companies like Abbott Laboratories have introduced portable POC devices such as the i-STAT system, facilitating rapid testing and quicker clinical decision-making at bedside or in emergency settings.
• Focus on Multiplex Molecular Diagnostics: The adoption of multiplex molecular diagnostic platforms is on the rise as healthcare providers look for faster, more comprehensive results. For instance, Roche Diagnostics has expanded its cobas® systems to offer multiplex panels capable of simultaneously detecting multiple pathogens and biomarkers, thus streamlining the sepsis diagnosis workflow and improving resource utilization.

• Expansion in Home-based and Remote Diagnostics: With the rise in telemedicine and remote patient management, there is increasing opportunity for companies like QuidelOrtho Corporation to expand their reach by developing at-home sepsis testing solutions, reducing hospitalization rates and enabling timely interventions.
• Strategic Collaborations with Hospitals and Research Institutes: There is significant potential for public-private collaborations, such as partnerships between Siemens Healthineers and academic medical centers, to develop next-generation biomarker-based sepsis diagnostic tests tailored for specific patient populations in North America.

• In April 2024, bioMérieux announced the launch of the VIDAS® KUBE™ next-generation immunoassay platform in North America for rapid detection of sepsis-related biomarkers. The new platform offers enhanced automation, reduced turnaround time, and a smaller footprint, designed to improve efficiency in high-throughput hospital laboratories.
• In June 2024, Roche Diagnostics received FDA clearance for its cobas® Liat system expansion for sepsis diagnostics, allowing for faster, multiplexed detection of pathogens directly from blood samples. This new approval is expected to streamline emergency room workflows and enable earlier, more precise interventions.
• In May 2024, Siemens Healthineers entered into a research partnership with the Mayo Clinic to co-develop novel proteomics-based sepsis diagnostic tests. The collaboration aims to translate cutting-edge biomarker discoveries into clinically actionable assays, supporting personalized sepsis management and advancing patient care in key North American health systems.